Stock code: 002653.SZ

Back

Haisco is listed in the "2026 Top 100 in Pharmaceutical R&D Strength" and "2026 TOP100 in Chemical Drug R&D Strength".

11th Session2026 PDI Pharmaceutical R&D·The Innovation Conference and the Top 100 Pharmaceutical R&D List were released in Chengdu recently. Haisco Medicine Group was also included in the list.2026Top 100 in Comprehensive Pharmaceutical R&D Strength Rankings2026Pharmaceutical R&D CapabilityTOP100》, ranked among the top 100 in overall drug research and development capabilities22Ranked among the top in the country for drug research and development capabilities7Position. The R&D and innovation capabilities have once again received high recognition in the industry.

PDI Pharmaceutical R&D & Innovation Conference is organized under the guidance of China Pharmaceutical University and the China Pharmaceutical Enterprise Management Association. It is a professional conference with high industry influence in the field of pharmaceutical R&D in China. The top 100 R&D list released this time conducts comprehensive evaluations across multiple dimensions such as R&D investment, innovative pipelines, patent layout, product transformation, and clinical progress, objectively reflecting the development level of innovative drug R&D in China and the innovation capabilities of enterprises.